Several vaccine companies in the COVID-19 outbreak rejoiced

Wen: Ko Zhikangxi: COVID-19 vaccine manufacturers are expected to split the $38 billion market.
biggest winners are likely to be Pfizer and its partner BioNTech, the first to market the mRNA vaccine.
Pfizer expects to sell $15 billion of COVID-19 vaccines with BioNTech in 2021.
was the first company to license the COVID-19 vaccine in developed countries.
Pfizer has delivered 65 million doses of vaccines worldwide by the end of January 2021, expects to supply 200 million doses to the U.S. by the end of May, and says it can produce 2 billion doses worldwide by 2021.
same time, Pfizer's mRNA vaccine rival, Moderna, has also received significant funding from its COVID-19 vaccine, mRNA-1273.
that as of mid-January, Moderna had received $11.7 billion in advance orders for vaccines from governments and organizations, and the company was in talks about more deals.
, Chief Executive Officer of Moderna, said in an interview that the company could join the ranks of the largest vaccine makers in terms of revenue this year.
year ago, Moderna didn't have any approved products.
analysts predict that, in addition to Pfizer and Modelna, AstraZeneta, Johnson and Johnson andNovax will also have billions of dollars in opportunities in 2021.
However, nonprofits are now pushing Pfizer and Modena, as well as other pharmaceutical companies such as Eli Lilly, Gilead, Merck and Co. and Regeneron, to provide information about their drug and vaccine pricing decisions on the grounds that they have received federal funds to supply, develop or expand production.
: GlaxoSmithKline GSK predicts that COVID-19 immunization campaigns could delay vaccination of its shingrix vaccine by several months.
Hasinggrix has been a major driver of GSK's sales growth.
2020, Shingrix achieved sales of $2.71 billion, a marked slowdown in year-over-year growth of 11 percent, and sales more than doubled in 2019.
blockade caused by COVID-19 has led to a sharp reduction in vaccination numbers, and GSK expects Shingrix to be out of service in the U.S. until at least the second half of 2021 as the outbreak continues to rage.
, governments' priority vaccination of COVID-19 vaccines could have a significant impact on all adult vaccinations, including Shingrix.
The Centers for Disease Control and Prevention (CDC) currently recommends a minimum 14-day interval between vaccination with COVID-19 and other vaccines, plus two doses of COVID-19 vaccine, and a window between injections that could delay vaccination of Shingrix by several months.
the COVID-19 epidemic has more widely damaged some of GSK's traditional vaccine businesses, such as the hepatitis vaccine.
U.S. back-to-school vaccinations were also suspended because schools delayed or canceled face-to-face classes.
2020, vaccine franchise sales were $9.53 billion, down 2% year-on-year.
GSK expects sales in the sector to be flat or maintain low single-digit growth in 2021 if vaccination rates pick up in the second half of the year.